Wednesday, December 11, 2013

For some patients with advanced breast cancer, chemo may be enough and they can be spared from the ordeal of going through surgery and radiation

It’s not been much time when Angelina Jolie initiated a “to go for or not to go for mastectomy” debate after being found with mutation in one of those ‘breast cancer risk prone gene BRCA1’. Well before you decide to go under a knife of surgeon, this could be a worth considering study that just came up from a very experienced physician based in India, which you want to discuss with your team of doctors.  

In a very prestigious AACR meeting currently ongoing in San Antonio, namely “2013 San Antonio Breast Cancer Symposium, held Dec. 10–14” Dr. Rajendra Badwe from Tata Memorial Hospital, Mumbai, India raised many eyebrows when he presented his findings in which he and his team led a study of 350 women with widely spread breast cancers that had shrunk after initial chemotherapy. Almost 50% of these patients went through mastectomy (surgery to remove the breast or the lump plus any cancerous lymph nodes). Rest of them did not have surgery. After about two years, 40 % of both groups were alive, suggesting that just chemotherapy could be enough. Women diagnosed with advanced breast cancer who respond well to chemotherapy get no additional benefit from having surgery and radiation afterwards. However, Dr. Rajendra Badwe, went on saying that options for surgery and radiation can be reserved for patients who need it for palliative reasons.
Targeting a specific area of the body for surgery or radiation is called loco-regional treatment, or LRT. Conventional wisdom has been that women with advanced (Stage 4) breast cancer, in which the disease has metastasized (spread to other organs), are treated only with chemotherapy unless other health issues (among them the relief of pain or other symptoms; the prevention of bone fractures; the tumor causing an open wound) dictate otherwise. In last decade, however, research community divided on into two school of thought on whether or not to use other supplementary treatment modalities such as surgery and radiation so they realized severe need of trials to confirm their theories. To find which of the two treatment methods resulted in the best survival outcomes for patients, Badwe and his colleagues in India, conducted a prospective, randomized, controlled trial funded by Badwe's hospital and the Department of Atomic Energy Clinical Trial Center in India.

Between 2005 and 2013 the researchers enrolled 350 women with metastatic breast cancer whose tumor responded positively to six cycles of chemotherapy. One group of patients received LRT, while the other group did not receive LRT. Both groups were matched for age, tumor size and extent of the metastases, and hormone receptor and HER2 receptor status.

Patients in the LRT group had either a lumpectomy or mastectomy and surgical removal of lymph nodes, followed by radiation treatment. All patients whose breast cancers were hormone-related received standard hormone therapy, regardless of the group to which they had been assigned.While the cancer was well-controlled in women who underwent surgery, that didn't translate into a survival advantage over the women who did not have surgery, Badwe said.The researchers also found a 7 percent excess death rate in patients who received LRT. The finding was not statistically significant, they said, but it aligned with the previous such findings that suggest surgical removal of the primary tumor in patients with advanced breast cancer might trigger the metastases.

“From a clinical practice point of view, as a surgeon I might know when to operate,” Dr. Badwe said. “But most importantly, when not to operate is equally important. “We need to know what the tumor is sensitive to,” Badwe said. “That is of greater value than loco-regional treatment.”

The extra expense of surgery and radiation, and the impact of those treatments on a patient’s quality of life also contribute to the researchers’ position that LRT should be done only within the tenets of clinical trials, he said.


While given the genetic differences between various populations, findings from this study have to be analyzed in that perspective, however, these findings open the door for more research on this aspect and warrant for more efforts towards new targeted therapies. 

Silence please! New siRNA data provides powerful free tool for biomedical research community !

A great example of public-private scientific collaboration between the NIH’s National Center for Advancing Translational Sciences (NCATS) and Life Technologies Corporation, we all now have access to a plethora of   information about how turning off a gene in laboratory by small interfering RNAs (which in my opinion is one of the most powerful tool used in the first decade of 21st Century biomedical research),  one at a time, could help us figure out their exact functions and learn more about how our health is affected when those functions are disrupted. Here is what NIH Director Dr. Francis Collins has to say about this collaborative project outcomes: 

http://directorsblog.nih.gov/2013/12/11/sirnas-small-molecules-that-pack-a-big-punch/#more-2362 


Silence please! New siRNA data provides powerful free tool for biomedical research

Monday, October 7, 2013

Wow, Three Americans Win Joint Nobel Prize in Medicine.

Congratulations to Drs. James E. Rothman, Randy W. Schekman and Thomas C. Südhof!! 

  • The 2013 Nobel Prize in Physiology or Medicine is awarded for discoveries of machinery regulating vesicle traffic, a major transport system in our cells.
  • Through their discoveries, Rothman, Schekman and Südhof have revealed the exquisitely precise control system for the transport and delivery of cellular cargo.
  • Disturbances in this transport system have deleterious effects and contribute to conditions such as neurological diseases, diabetes, and immunological disorders.





Each Scientist's contribution in brief:

i)  Schekman discovered a set of genes that were required for vesicle traffic. 

ii) Rothman unraveled protein machinery that allows vesicles to fuse with their targets to permit transfer of cargo. 

iii) Südhof revealed how signals instruct vesicles to release their cargo with precision.



How important their work is could simply be understood by one example. We are well aware about Diabetes as a disease as it affects so many people on the earth, we also are aware that insulin is the key protein that gets defective in Diabetes.  However, most of us do not know how Insulin, which controls blood sugar levels, is made and released into the blood at the right place at the right time, and how it gets outside of the beta cells of the pancreas (in case of healthy people). Modern antidepressants only work because they prevent neurons from re-uptake of the neurotransmitter serotonin. But how was that serotonin released in the first place? Answer to such questions that deal with trafficking of biological molecules is studied in the field of "vascular trafficking" in cell biology.  This field is all about cellular structures called "vesicles". These bubble-like bags of cellular goodies are one common way that the cells gets things from the inside to the outside, sending off their chemical messages from a few micrometers away to a couple of meters. Some brain disorders such as Huntington's 
and Alzheimer's diseases have also been attributed at least in part to defects in the vesicle transport systems.

It is interesting to note that Randy Schekman, who is actually a St. Paul (Minnesota) native, a place currently I live and work, who has been at the University of California at Berkeley for 35 years, did most of his work using simple organism called yeast. It proves again that non-human model systems  have given us crucial insights to how  human bodies function in healthy state and diseases.

It is also interesting fact that 2 of 3 laureates were trained with previous Nobel laureates. Scheckman did his graduate work with legendary molecular biologist Arthur Kornberg (Physiology or Medicine 1959) while Südhof was a postdoctoral fellow with the cholesterol biology pioneers at the University of Texas Southwestern Medical School, Michael Brown and Joseph Goldstein (Physiology or Medicine 1985). So like teacher like disciple

Dr. Jeremy Berg, director of the Institute for Personalized Medicine at the University of Pittsburgh who for years also worked as director of the National Institute of General Medical Sciences, a part of the National Institutes of Health, aptly summarized the importance of the field pioneered by these laureates:-
"It's one of the prizes for which there is not a treatment that came out of it directly, but there are probably literally thousands of laboratories around the world whose work would not be taking place the way it is without their work," 

I do not need to mention that even my area of interest (cancer biology with emphasis to adhesion signaling and receptor tyrosine kinase signaling) could not have been as exciting and promising if there were no such pioneering work done by these scientists trio. 

Monday, August 19, 2013

Cancer Care in India: Patented Cancer Drugs or Basic Radiation Therapy Units?

Rising cost of cancer treatment in India due to lack of generics for third generation wonder drugs  to treat cancer has recently initiated an interesting debate. See this:

http://www.nature.com/news/india-spurns-cancer-patents-1.13552


To me, this debate does not make any sense. Advocating for cheaper Trastuzumab for these unfortunate cancer patients from India sounds like crusading for a delicacy such as 'foie gras' for those who do not even have access to a piece of bread to get rid of hunger. Most of Indian cancer patients die of cancer even without being officially diagnosed with this disease. However, majority of the cancer patients are not dying because they can not afford to buy fancier third generation drugs such as lapatinib or trastuzumab, rather it is lack of basic infrastructure for cancer treatment such as availability of team of specialists including surgical oncologists, medical oncologists, experienced histopathologists (to make diagnoses on tumor biopsies), radiation oncology units with state-of-art equipments in every district level cities/towns in India. Most of the cancer patients in India are being diagnosed with it by general surgeons on the operation table while being operated for some other or associated benign conditions. 


Real journey of turmoil starts now for the families of these cancer patients when (with immense fear of losing their relative, compounded by their inability to arrange finances to be able to travel to one of those few metropolitan cities which is where cancer hospitals/centers are) they start searching for a good cancer center where they could manage to travel to and live within their meager resources for their patient's treatment. Getting their patient admitted in those cancer hospitals itself is a herculean task for these families. It is hard to believe that Uttar Pradesh, most populous state of India, does not have a single medical oncologist in the entire state. Cancer care in the state of Uttar Pradesh is totally in the hands of a few radiation therapists (~20 radiation therapists for a population of 20 million people) residing in < 4-5 functional radiation therapy units, who are over burdened with cancer patients. Most of these patients do have to wait for 2-3 months for their turn when their first radiation therapy session starts. On top of this, most of these sessions are often not complete either due to interruption in power supply in the middle of a session or radiation equipment being broken, making their cycle of therapy sessions incomplete or ineffective. 


Radiotherapy (RT) is one of the major modalities of cancer treatment and about 60% of these patients, no matter which type or stage of cancer they have, will require RT as curative or palliative (reducing symptoms of the disease) intent. International guidelines recommend one megavoltage therapy equipment for every 1,20,000 population, for every 250 new patients providing about 6,250 treatments per year. These calculations are based on the assumption that 50% of the patients could be treated for cure (30 to 40 increments) and 50% of the remaining, for palliation (10 to 20 increments). Therefore, 125 patients × 35 treatments (4375) and 125 patients × 15 treatments (1875), respectively, totaling to 6250 treatments. Taking all types of patients treated and various type of treatments, the above number appears legitimate for planning treatment facilities in an RT center (Ravichandran et al., 2009).

Many cancer centers in India still lack capabilities of simple techniques for tumor localization such as iso-centric simulator x-ray machines, treatment planning systems, 3D imaging capabilities, and mould room facilities. In India, for a population of about 1.1 billion, at the cancer incidence rate of 70 per 100,000 population, 60% of them requiring radiation therapy, they would need about 1155 machines assuming a load of 400 per treatment machine annually. Presently, there are only 400 Cobalt-60 teletherapy
machines (very basic first generation radiation therapy machine which is no more used in any developed country), about 25% of them served more than 10 years (which is way beyond their normal age; 5-7 years) needing urgent replacements, thus making majority of them non-functional, or even non-effective. Availability of only 1/3 rd number (half of that 1/3rd number of available units are non-reliable too boot) of machines compromises with the quality of patient care which may have implications in the optimal outcome. This grim scenario definitely needs improvement.  


As mentioned earlier, Cobalt 60 unit which is what is most commonly used radiotherapy equipment available in India, has become obsolete and has been long replaced by Linear Accelerator (Linac) machines in developed world. Cobalt 60 units provide relatively high energy gamma rays for radiotherapy which are ideally suited for treatment of head and neck cancers and other superficially located tumors such as breast cancers. They are not adequate for treatment of deep seated tumors and have the added disadvantage of decreasing output with decay of source and the need for source replacement within 5-7 years. Disposal of decayed source is another major concern. The edges of the radiation beams coming out of a Linac machine are much more sharply defined than those of a cobalt machine, allowing additional precision in dose delivery. The dose rate per minute is variable and can be turned up very high allowing the patient to be located at substantial distance from the machine in order to create large fields necessary for total skin or total body irradiation while still maintaining adequate dose rate. With cobalt, the rate is determined by the amount of cobalt source in the machine and cannot be regulated. This is why Linac machines are safer and cause lesser side-effects which is a very important considerations for Indian patients most of whom especially women patients are malnourished and can not survive the side-effects of radiotherapy given by Cobals 60 machines. 



Building basic infrastructure for effective and functional radiotherapy units for the whole country will have long term economical impact as well for the general health of a country like India where more and more people are going to live longer, owing to the recent advances in bio-medical sciences such as better immunization programs, availability of life saving medicines and enough food to feed more people than ever in the past. Radiotherapy is not even expensive, especially considering the size of budget India allocates for buying new military gadgets, and their ambitious project to go to the moon in near future. Most of us will be surprised to note that the cost of ~1 military jet fighter is almost comparable to the entire cost for radiation therapy for most average sized countries. In fact, together with surgery, radiotherapy still remains the most cost-effective way of curing cancer. 


I am not against making third generation wonder drugs (which are still covered by foreign patent laws) cheaper for developing countries like India, but focusing solely on this aspect is going to serve only a minority of patients and distracts from the real issue of building basic infrastructure for cancer care. Also, these 3rd generation drugs are not the permanent cure, all they do is probably add few months to few years in the life of a cancer patient. Better attention to basic research to find out etiology of many unique cancer types prevalent in Indian patients, developing prevention strategies, new clinical trials, opening new and more cancer care centers in every district level towns, and most importantly training new generation of physicians in several sub-specialties of oncology is the key which could enable Indian health-care system to fight cancer. 






Bibliography: Ravichandran R. Has the time come for doing away with Cobalt-60 teletherapy for cancer treatments. J Med Phys. 2009 Apr;34(2):63-5.

Friday, June 14, 2013

Visual Inspection with Vinegar (VIN) Based Cervical Cancer Screening Significantly Reduces Cancer Deaths

Few weeks ago Angelina Jolie made it big news by revealing her prophylactic mastectomy. Whether or not you agree with her decision of going through mastectomy just because of those silly genes, one thing you would not be able to disagree on that she prompted general public worldwide to google these exotic sounding words “BRCA1 and BRCA2” genes (now better known as “Angelina Jolie genes”) which so far used to be the part of only scientific discussions confined within the fraternity of cancer researchers. Kudos to Angelina Jolie and her celebrity power that this subject is now being discussed among women worldwide who indeed need to know about it all more than anyone else. I can’t help but believe that yesterday’s Supreme Court (US) decision to wipe patents on Angelina Jolie genes (BRCA1 and BRCA2) was also somehow got positively influenced by the debate recently initiated by Angelina Jolie’s revelation, otherwise this legal battle was ongoing in the courts for years with no conclusive outcome as it happened this yesterday. Irrespective of your quest for findings elements of right or wrong in this landmark decision, people of all walks of life, especially scientists and cancer patients have welcomed this court ruling with equal applause. I will discuss this issue later in my future postings.

Today, the topic that brought me here is very close to my heart for several reasons including a personal one. From last week’s breaking advances in the field of cancer research, I thought of picking this piece of research work, because I consider it as a big feat achieved by scientists from India, a third world country, where even a thought of having an standard cancer care infrastructure seems to be a luxury, given the dire need for general physicians and infrastructure to treat bacterial and viral diseases. This was one of the highly talked about and praised research work recently discussed at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago last week, in which over 26,000 cancer scientists and clinicians attended this meeting and thousands of research studies, small and large were reviewed by the scientific fraternity. Because ASCO is the world’s most dominant oncology specialty group, the discussions and recommendations set the standard for cancer care in the world. 

Well, a research team led by Surendra Srinivas Shastri, MD, a professor of preventive oncology at Tata Memorial Hospital (oldest and probably single dedicated cancer hospital and research center in India, a country of 1.25 billion people) in Mumbai, India, developed a simple screening technique using an inexpensive chemical agent, vinegar or acetic acid, dramatically reduced deaths related to cervical cancer in a large population of Indian women. This powerful study shows that how just “visual inspection with acetic acid or (VIA)”, conducted by non-medical personnel trained to deliver basic healthcare (paramedical staff), could cut the death rate by 31%.

One of the most important aspects of this finding lies in the fact that this strategy is highly effective and can be implemented on a broad scale in low-income countries. "There was almost no overdiagnosis, it doesn't require a laboratory, and it can be widely implemented in the lowest-resource settings, such as India," said lead study author Dr. Shastri. "If implemented at national level in India, it could prevent 22,000 cervical cancer deaths," said Dr. Shastri, who presented the findings of this large randomized trial during a plenary session at the 2013 Annual Meeting of ASCO in Chicago. He went on to say that "if taken globally to the lowest-resource countries, this method could prevent around 72,000 deaths in the developing world."

Cervical cancer is the leading cause of cancer-related mortality in women in many developing nations, where access to Pap test screening (gold standard screening method for diagnosing early stage cervical cancer) is very limited or nonexistent. Widespread Pap test screening in high-income countries has significantly reduced the incidence and subsequent death rate from cervical cancer by 80%. Unfortunately, from my own experience of talking to Indian women (I am originally from India, and keep visiting India almost every year) in my own extended family and friends, my impression is that even educated women have not heard of Pap test screening methods, let alone thinking of asking their primary care physicians to write a pathology test for this.   

Apart from lack of awareness about health issues among common people in India, "There is no cervical cancer screening program in India because it is not feasible," explained Dr. Shastri. "There is inadequate infrastructure, a lack of trained human resources, logistic difficulties, and a relatively high cost."

Therefore, the researchers looked at VIA, which is a simple visual test that can be done without laboratory support. "It consists of an application of 4% vinegar to the cervix, and the results are available in 1 minute," Dr. Shastri explained. "Paramedical workers can be trained in 4 weeks."

VIA screening method is validated
Another cancer researcher and leader in the field and also discussant for the study during the plenary session, Electra D. Paskett PhD, professor of medicine at the Ohio State University Comprehensive Cancer Center in Columbus is very enthusiastic about this pioneering study, “What is unique about this study is that it was conducted in the slums of Mumbai in an unscreened population, and participation was high and the size of the sample was large. What is essential here is the fact that both diagnostic and treatment services were available to women in both arms without any charge."

Dr. Paskett also pointed out that there are several take-home messages from this study; 1) that the VIA method has been validated, 2) it has been accepted, 3) it is inexpensive, 4) can be used in low-resource areas, and 4) can save lives.

Study Details
In this clinical trial, VIA screening technique was performed by community-based nonmedical primary health workers trained to provide basic healthcare services in regions that lack physicians and nurses. The researchers had to pass through several layers of community barriers, such as community leaders and religious leaders, before being able to speak with the women. It is noticeable that India is home to several religiously conservative communities and preventive measures in the past such as polio vaccination program had to face a lot of resistance in these communities.  "We involved the community, giving them a sense of participation, and we were able to create as sense of community ownership," Dr. Shastri said. "This ensured better participation."

Dr. Shastri and colleagues initiated this cluster randomized controlled trial in 1998 to evaluate the ability of VIA screening to reduce cervical cancer mortality. The participants were 35 to 64 years of age and had no history of cancer. The study design involved 20 clusters, with an average of 7500 eligible women in each cluster. Ten such clusters served as the screening group (n = 75,360) and 10 served as the control group (n = 76,178). From statistical point of view, this is one of the very large and powerful research studies in the history of recent clinical trials.
Primary health workers or paramedical staff did conduct 4 rounds of cancer education and VIA screening at the intervals of 24 months in each screening group. In the control group (a group of people, which was not screened by VIA, usually having such population groups are part of standard study method to conduct a scientific experiment and used as population to compare the results against), cancer education was offered once at recruitment.

Reduction in Mortality Rate
Although the researchers had planned for a 16-year study, they analyzed results at 12 years. Compliance was high, with 89% participation in screening and 79% compliance with postscreening diagnostic confirmation. The researchers note that the quality of screening performed by the primary health workers or paramedical health care workers was almost comparable to that of an experienced gynecologist.

The incidence of invasive cervical cancer was very similar in the screening and control groups (26.74 vs 27.49 per 100,000). However, for those with invasive cancer, treatment compliance was higher in the screening group than in the control group (86.34% vs. 72.29%). In the screening group, there was a 31% drop in mortality related to cervical cancer, compared with the control group (P = 0.003).

In addition to the decrease in deaths related to cervical cancer, there was also a 7% reduction in all-cause mortality (RR, 0.93; P = .41), possibly due to the fact that these patients enrolled in VIA screening program had better/timely access to medical interventions.  

On the basis of these results, the Indian health officials in the state of Maharashtra, a western province of India, where the trial was conducted, are preparing to train primary health care workers to provide VIA screening to all women 35 to 64 years of age at 24-month intervals. In addition, the Indian government is working to implement nationwide VIA screening, and is planning to reach out to other low- to moderate-income countries to share these results and offer assistance with training.

Interestingly this study was financially supported by the National Institutes of Health (NIH), USA, and Women's Cancer Initiative. Just confirms the belief that science does not care of physical boundaries, it helps humanity in general.


Take home message – while developments in state-of-art biomedical technologies are certainly needed to keep this fight alive against this dreaded disease cancer, we must not ignore the power of old fashioned scientific methods such as visual inspection with acetic acid (VIA) which can significantly reduce the death rate by cancers in the major part of the world. 

Friday, June 7, 2013

Very Inspiring Story

Just gives a glimpse of the lives of scientists about we do in our laboratories, and how our determination to do what we do everyday is strengthened by incidences that touch our own lives. Kudos to Dr. Igor Astsaturov (a former colleague, philosopher, and friend for me) who, I am confident, will soon be able to help other patients with pancreatic cancers with his newly identified drug...!!

http://www.huffingtonpost.com/jessica-wapner/driven-by-love-a-step-for_b_3396927.html


   

Wednesday, April 10, 2013

Endometrial Hyperplasia

When a relative of mine got diagnosed with a condition called “Endometrial Hyperplasia” and she and others among family and friends became curious about it, I thought of providing some basic information regarding this condition:    

What is endometrial hyperplasia?

 

Endometrium, is the tissue that lines the UTERUS. Endometrial hyperplasia occurs when the endometrium, the lining of the uterus, becomes too thick. It is not cancer, but in some cases, it can lead to cancer of the uterus. Endometrial hyperplasia is indeed a precursor to the most common gynecologic cancer diagnosed in women, which is “endometrial cancer” of endometrioid histology. It is most often diagnosed in postmenopausal women, but women at any age with unopposed estrogen from any source are at an increased risk for developing endometrial hyperplasia.

How does the endometrium normally change throughout the menstrual cycle?

The endometrium changes throughout the menstrual cycle in response to hormones. During the first part of the cycle, the hormone estrogen is made by the ovaries. Estrogen causes the lining to grow and thicken to prepare the uterus for pregnancy. In the middle of the cycle, an egg is released from one of the ovaries (ovulation). Following ovulation, levels of another hormone called ‘progesterone’ begin to increase. Progesterone prepares the endometrium to receive and nourish a fertilized egg. If pregnancy does not occur, estrogen and progesterone levels decrease. The decrease in progesterone triggers menstruation, or shedding of the lining. Once the lining is completely shed, a new menstrual cycle begins.

What causes endometrial hyperplasia?

Endometrial hyperplasia most often is caused by excess estrogen without progesterone. If ovulation does not occur, progesterone is not made, and the lining is not shed. The endometrium may continue to grow in response to estrogen. The cells that make up the lining may crowd together and may become abnormal. This condition, called hyperplasia, may lead to cancer in some women.

When does endometrial hyperplasia occur?

Endometrial hyperplasia usually occurs after menopause, when ovulation stops and progesterone is no longer made. It also can occur during perimenopause, when ovulation may not occur regularly. Listed as follows are other situations in which women may have high levels of estrogen and not enough progesterone:

        Use of medications that act like estrogen

        Long-term use of high doses of estrogen after menopause (in women who have not had a hysterectomy)

        Irregular menstrual periods, especially associated with polycystic ovary syndrome or infertility

·         Obesity

What risk factors are associated with endometrial hyperplasia?

Endometrial hyperplasia is more likely to occur in women with the following risk factors:

• Age - older than 35 years

• White race

• Never having been pregnant

• Older age at menopause

• Early age when menstruation started

• Personal history of certain conditions, such as diabetes mellitus, polycystic ovary syndrome, gallbladder disease, or thyroid disease

• Obesity

• Cigarette smoking

• Family history of ovarian, colon, or uterine cancer

 

What are the types of endometrial hyperplasia?

Endometrial hyperplasia is classified as simple or complex. It also is classified by whether certain cell changes are present or absent. If abnormal changes are present, it is called atypical. The terms are combined to describe the exact kind of hyperplasia:

• Simple hyperplasia

• Complex hyperplasia

• Simple atypical hyperplasia

• Complex atypical hyperplasia

 

What are signs and symptoms of endometrial hyperplasia?

The most common sign of hyperplasia is abnormal uterine bleeding. If you have any of the following, you should see your obstetrician–gynecologist:

• Bleeding during the menstrual period that is heavier or lasts longer than usual

• Menstrual cycles that are shorter than 21 days (counting from the first day of the menstrual period to the first day of the next menstrual period)

• Any bleeding after menopause

 

How is endometrial hyperplasia diagnosed?

There are many causes of abnormal uterine bleeding. If you have abnormal bleeding and you are 35 years or older, or if you are younger than 35 years and your abnormal bleeding has not been helped by medication, your obstetrician–gynecologist may perform diagnostic tests for endometrial hyperplasia and cancer.

Transvaginal ultrasound may be done to measure the thickness of the endometrium. For this test, a small device is placed in your vagina. Sound waves from the device are converted into images of the pelvic organs. If the endometrium is thick, it may mean that endometrial hyperplasia is present.

The only way to tell for certain that cancer is present is to take a small sample of tissue from the endometrium and study it under a microscope. This can be done with an endometrial biopsy, dilation and curettage, or hysteroscopy.

 

What treatments options are available for endometrial hyperplasia?

In many cases, endometrial hyperplasia can be treated with progestin. Progestin is given orally, in a shot, in an intrauterine device, or as a vaginal cream. How much and how long you take it depends on your age and the type of hyperplasia.

Treatment with progestin may cause vaginal bleeding like a menstrual period.

If you have atypical hyperplasia, especially complex atypical hyperplasia, the risk of cancer is increased. Hysterectomy usually is the best treatment option if you do not want to have any more children.

For more details, please read this review article:

http://utilis.net/Morning%20Topics/Gynecology/Endometrial%20Hyperplasia.pdf

 

What can I do to help prevent endometrial hyperplasia?

You can take the following steps to reduce the risk of endometrial hyperplasia:

• If you take estrogen after menopause, you also need to take progestin or progesterone.

• If your menstrual periods are irregular, birth control pills (oral contraceptives) may be recommended. They contain estrogen along with progestin. Other forms of progestin also may be taken.

• If you are overweight, losing weight may help. The risk of endometrial cancer increases with the degree of obesity.

 

Technical Terms:
Cells: The smallest units of a structure in the body; the building blocks for all parts of the body.
Diabetes Mellitus: A condition in which the levels of sugar in the blood are too high.
Dilation and Curettage: A procedure in which the cervix is opened and tissue is gently scraped or suctioned from the inside of the uterus.
Endometrial Biopsy: A test in which a small amount of the tissue lining the uterus is removed and examined under a microscope.
Endometrium: The lining of the uterus.
Estrogen: A female hormone produced in the ovaries that stimulates the growth of the lining of the uterus.
Hormones: Substances produced by the body to control the function of various organs.
Hysterectomy: Removal of the uterus.
Hysteroscopy: A procedure in which a slender, light-transmitting device, the hysteroscope, is inserted into the uterus through the cervix to view the inside of the uterus or perform surgery.
Intrauterine Device: A small device that is inserted and left inside the uterus to prevent pregnancy.
Menopause: The time in a woman’s life when the ovaries have stopped functioning, defined as the absence of menstrual periods for 1 year.
Menstruation: The monthly discharge of blood and tissue from the uterus that occurs in the absence of pregnancy.
Ovulation: The release of an egg from one of the ovaries.
Perimenopause: The period preceding menopause that usually extends from age 45 years to 55 years.
Polycystic Ovary Syndrome: A condition in which levels of certain hormones are abnormal and small growths called cysts may be present on the ovaries. It is associated with infertility and may increase the risk of diabetes mellitus and heart disease.
Progesterone: A female hormone that is produced in the ovaries and that prepares the lining of the uterus for pregnancy.
Progestin: A synthetic form of progesterone that is similar to the hormone produced naturally by the body.
Transvaginal Ultrasound: A type of ultrasound in which a transducer specially designed to be placed in the vagina is used.
Uterus: A muscular organ located in the female pelvis that contains and nourishes the developing fetus during pregnancy.
 

                                                                                Courtesy: The American College of Obstetricians and Gynecologists

Friday, March 15, 2013

Bruce Alberts on Future of American Science



“I have seven grandchildren, and I worry about their future. The nation that I was raised in, the United States, has clearly lost its way at a time when the world badly needs wise leadership. Nations with a long-term view are making huge investments in their infrastructure—transportation, water, energy, waste, and recreation. And they have a laserlike focus on supporting science and engineering research with government resources. As examples, Germany, China, and South Korea come to mind. Meanwhile, the United States is living off its past. Not only do we face a crumbling infrastructure but our federal investments in fundamental long-term R&D have been stagnant, dropping from 1.25% of the gross domestic product (GDP) in 1985 to 0.87% in 2013.† Now, on top of that comes a mindless budget "sequester" that will make the situation considerably worse, causing the U.S. National Science Foundation to announce last week that it may award 1000 fewer research grants in 2013 than it did in 2012.

                                                     - Bruce Alberts (Science

 
This is not a thought of an average US citizen. Dr. Alberts, a past president of National Academy of Sciences, Editor-in-Chief of famous journal “Science”, is also a path breaking scientist in this own right, a leader, and visionary in American Science. Almost everyone in our generation of molecular biologists grew up reading his classic book during our college days that inspired us making our career in this field. His concerns seem quite genuine.
 
One study predicts that 2023 may be the year that America loses its global Research & Development (R&D) leadership.
China is on its track to overtake the U.S. in spending on research and development in ~ 10 years, as federal R&D spending (in the U.S.) either declines or remains flat.
 
However, it should not be forgotten that the United States still maintains a large lead in R&D spending over China, with federal and private sector investment expected to reach $424 billion next year, a 1.2% increase.
 
By contrast, China's overall R&D spending is $220 billion next year, an increase of 11.6% over 2012, a rate similar to previous years, according to the 2013 Global R&D Funding Forecast prepared by Battelle, a research and technology development organization, and R&D Magazine. "The U.S. still has a significant lead and advantage in R&D over all of these countries," said Martin Grueber, one of the authors of the report and a lead researcher at Battelle, "but the concern is R&D is a long-term investment, and as these other countries continue to grow their R&D capabilities ... how long can we maintain that advantage?"



 
A major share of R&D research in the U.S. is funded by the federal government, which is expected to budget $129 billion for R&D next year, a decline of 1.4%. This figure could decrease even further if Congress does not resolve its budget impasse.
 
Government R&D spending is considered significant as  because, unlike the private sector, it funds basic research. This is research that often takes years or decades to yield results, but it can also lead to new industries and jobs. Basic research is the back bone of industrial growth in any economy.
Other emerging economies, besides China, are also spending more on R&D. India, for instance, will invest about $45 billion next year in R&D, an increase of just over 12%.
 
President Obama has called for national R&D expenditures equal to 3% of GDP, which includes private and government investment. The forecast for next year is 2.66% of GDP, according to the Battelle forecast.

The White House also believes that China may overtake the U.S. in R&D spending.
"China's investment as a percentage of its GDP shows continuing, deliberate growth that, if it continues, should surpass the roughly flat United States investment within a decade," said the President's Council of Advisors on Science and Technology.

One significant but often ignored aspect of R&D operations conducted by U.S. is offshoring, which according to the White House report, "has negative long-term consequences for the United States."
The report also said that R&D returns to the U.S. economy are "likely highest when the research is both generated and used within the United States."
 



With a battery of talented scientists, engineers, medical doctors, present in the country, future of American excellence in Science and Technology is still bright, provided political leadership is honest and strong enough to resolve this issue sooner and act faster. Unfortunately, this is the most disheartening part – US Congress does not appear likely to take steps in the near term to improve R&D spending. Hope they are listening to what Dr. Alberts is echoing in his editorial piece this week.